Propanc Biopharma Initiates First Tranche Of $500K Stock Buyback Plan
Propanc Biopharma, Inc. (NASDAQ: PPCB ) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has initiated a share repurchase program authorizing the Company to repurchase a first tranche of up to $500,000 over the next 30-day period.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.